Skip to content

Li-Hep vs. Non-Li-Hep Coated Transfer Device

Sample Comparison With Siemens® Point-of-care Device for Cardiac Troponin I Assay by Using a Heparin Coated Transfer Device vs. Non-heparin Coated Transfer Device at the Emergency Department (Validation Study 2.0)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04458155
Enrollment
70
Registered
2020-07-07
Start date
2020-06-18
Completion date
2021-04-01
Last updated
2022-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Cardiac Ischemia, Chest Pain, Myocardial Infarction

Keywords

Troponin, Point-of-care, Acute coronary syndrome, Siemens, Chest pain

Brief summary

This study is a prospective, diagnostic, cohort study within the standard care of acute coronary syndrome (ACS) patients. It compares the analytical performance of Siemens® point-of-care high sensitive troponin I testing in venous, plasma and capillary sample types. The investigators hypothesize that there is a good correlation between the Siemens® POC HS cTnI assay results for the three sample types and that the bias between different POC sample types reduces from \ 10% to ≤ 5% when using heparinized transfer device for the capillary sample.

Detailed description

In September 2019, the validation study 1.0 started, in which the cTnI result of the Siemens POC device on three sample types are compared. Interim analysis of the sample comparison was performed by regression analysis using Passing and Bablock, and calculating the Pearson correlation coefficient. The Li-hep Plasma vs Li-hep venous blood show a very good correlation of 1.00-1.03 with an R of \>0.99, so the results between these sample types can be used interchangeably. For the capillary sample vs the Li-hep sample (both blood and plasma) the slope is 8-12% higher. With a 8-12% higher response, the capillary test results may not be interchangeably used with the other 2 sample types. It is remarkable that capillary samples give a higher response, since it was anticipated that the result may be slightly lower due to the possible dilution by interstitial fluid. The investigators hypothesize that the presence of the Li-heparin anti-coagulant in the venous draw lead to a slight reduction of the apparent cTnI concentration. By using a heparin coated transfer device for the capillary samples instead of an uncoated transfer device, this hypothesis will be tested.

Interventions

DEVICESiemens® Point-of-care high sensitive troponin I analyzer

Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Siemens® device.

Sponsors

Siemens Corporation, Corporate Technology
CollaboratorINDUSTRY
VieCuri Medical Centre
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Age 18 years or older. * Referred to cardiac ED with chest pain suspected of ACS; inclusion at arrival (T=0) or one hour after arrival (T=1). * Subacute STEMI or NSTEMI patients admitted at the CCU who have an indication for coronary angiography but do not need rescue/emergency PCI. * STEMI patients who already underwent rescue/emergency PCI; inclusion post PCI.

Exclusion criteria

* Out of hospital cardiac arrest. * Patients with sudden onset tachycardia and a frequency of 110 bpm or higher (supraventricular or ventricular). * Patients who are hemodynamically unstable or in which an acute non-coronary diagnosis is suspected, e.g. pulmonary embolism, thoracic aortic dissection etc. * Patients recently already admitted for the same set of symptoms at a previous healthcare institution before being transferred to the participating clinical site. * Patients not willing or not able to provide informed consent due to their medical condition as judged by the physician.

Design outcomes

Primary

MeasureTime frameDescription
Sample comparison30 daysThe primary objective is to compare the analytical performance of Siemens® point-of-care high sensitive troponin I testing in different sample types by using the coefficient of variation. This comparison will comprise Siemens® POC capillary vs. Siemens® POC venipuncture and vs. Siemens® POC plasma (Sample comparison). The primary objective will be achieved by taking: * Two capillary samples \> one sample with a heparin coated transfer device (drawn from a finger of the right hand) and the other one with a non-heparin coated transfer device. (drawn from a finger of the left hand) * One extra venous blood sample \> for POC venous and POC plasma analysis. Trained clinical staff will collect the different samples. All samples will be collected once, at one time point with a maximum of 10 minutes in between.

Secondary

MeasureTime frameDescription
Linear regression and Pearson's correlation.30 daysThe relationship between POC sample types by linear regression and Pearson's correlation.
Overview baseline characteristics.30 daysTo create an overview of baseline characteristics of the population.
Bland-Altman method30 daysTo compare the analytical performance of Siemens® point-of-care high sensitive troponin I testing in different sample types by using the Bland-Altman method.
Modified HEART score30 daysTo determine the modified HEART score retrospectively based upon POC capillary results in the population.
Modified HEART score comparison30 daysTo compare the retrospectively determined modified HEART score based upon POC capillary heparin coated transfer device with the retrospectively determined modified HEART score based upon POC capillary non-heparin coated transfer device.
Major adverse cardiac event (MACE)30 daysMACE is is defined as a composite of cardiac death and myocardial infarction.

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026